Dry eye disease therapy widens past topical anti-inflammatory standards
TRPM8-pathway agents, novel mucin-pathway therapy, and engineered tear formulations are restructuring dry eye disease management.
Dry eye disease has been a topical-cyclosporine, lifitegrast, and tear-supplement story for years. TRPM8-pathway agents (varenicline nasal spray for dry eye), novel mucin-pathway programs, and engineered tear formulations are reshaping the category. The diagnostic-pathway question (subtype-specific therapy: aqueous-deficient vs evaporative) is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is presbyopia?
- SnapshotPresbyopia therapy reference (2026)